Cargando...
Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients
What is already known about this subject Before this study, few data were available on the potential effect of genetic variants of P-glycoprotein or the CYP3A5 enzyme on the pharmacokinetic variability of protease inhibitors (PI). MDR1 C3435T polymorphism was often linked with the pharmacokinetic va...
Gardado en:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Blackwell Science Inc
2007
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2000655/ https://ncbi.nlm.nih.gov/pubmed/17517050 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2007.02903.x |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|